Pharmaceutical
Technology
Health

Agios

$66.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$3.18 (5.07%) Today
+$0.08 (0.12%) After Hours

Why Robinhood?

You can buy or sell Agios and other stocks, options, ETFs, and crypto commission-free!

About

Agios Pharmaceuticals, Inc. Common Stock, also called Agios, is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. Read More It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Employees
482
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
3.65B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
445.71K
High Today
$66.13
Low Today
$63.26
Open Price
$63.53
Volume
176.34K
52 Week High
$99.82
52 Week Low
$41.63

Collections

Pharmaceutical
Technology
Health
Biotechnology
Biopharmaceutical
Cancer Prevention
2013 IPO
US

News

Seeking Alpha6h

Agios' Tibsovo a Breakthrough Therapy for certain type of AML

The FDA designates Agios Pharmaceuticals' (NASDAQ:AGIO) TIBSOVO (ivosidenib), in combination chemo agent azacitidine, a Breakthrough Therapy for the treatment of newly diagnosed adult patients at least 75 years old with IDH1 mutation-positive acute myeloid leukemia (AML) who have comorbidities that preclude intensive induction chemotherapy.

1
Yahoo Finance6h

Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in

CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for TIBSOVO® (ivosidenib) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation in adult patients who are ≥75 years old or who have comorbidities that preclude...

3
Simply Wall St9h

Should You Be Worried About Insider Transactions At Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)?

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So before you buy or sell Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), you may well want to know whether insiders have been buying or selling. Do Insider Transactions Matter? It’s quite normal to see company insiders, such as board members, trading in company stock, from time to time. Howeve...

2

Earnings

-$1.81
-$1.60
-$1.40
-$1.19
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 3, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.